SARS-CoV-2: Current Tools to Fight COVID-19 ST-Elevation Myocardial Infarction.
| Autor: | Ifthikar S; Cardiology, HCA Healthcare Riverside, Riverside, USA., Savoj J; Cardiology, HCA Healthcare Riverside, Riverside, USA., Singh H; Internal Medicine, HCA Healthcare Riverside, Riverside, USA., Hu P; Interventional Cardiology, HCA Healthcare Riverside, Riverside, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Aug 15; Vol. 15 (8), pp. e43539. Date of Electronic Publication: 2023 Aug 15 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.43539 |
| Abstrakt: | The capacity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to wreak havoc on the inflammatory and coagulation pathways via the cytokine storm has led to over 6.3 million fatalities globally. Based on recent data, the mechanism predominately involves the formation of microvascular thrombosis when pertaining to cardiovascular disease. However, a subset of coronavirus disease-2019 (COVID-19)-positive patients present emergently with acute ST-elevation myocardial infarction (STEMI) are found to have severe epicardial thrombosis which is refractory to traditional coronary revascularization. We have noted mortality in these patients presenting to our facility to be as high as 90% and all angiographically confirmed to have thrombus which was refractory to traditional therapy. We present a case series of COVID-19-positive patients presenting with STEMI found to have epicardial thrombus who were treated with different traditional STEMI therapies but with fatal outcomes. Other possible techniques including mechanical thrombectomy, optimizing traditional and nontraditional anticoagulation therapy with the use of early hemodynamic support may prove more efficacious to destroy thrombus and potentially improve mortality. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Ifthikar et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|